<DOC>
	<DOC>NCT01441206</DOC>
	<brief_summary>The purpose of this study is to learn more about the safety and dosing of rifampin in infants.</brief_summary>
	<brief_title>Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants</brief_title>
	<detailed_description>Pharmacokinetics and safety of rifampin will be studied in term and preterm infants who are receiving rifampin per standard of care.</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Cohort 1: Suspected systemic infection Infant &lt; 121 days of age at the time of 1st dose of rifampin administration Sufficient intravascular access (either peripheral or central) to receive rifampin. Cohort 2: Receiving rifampin per local standard of care. Infant &lt; 121 days of age at the time of 1st dose of rifampin administration Cohort 1: History of allergic reactions to rifampin Aspartate aminotransferase (AST) greater than 3 times upper limit of normal Alanine aminotransferase (ALT) greater than 3 times upper limit of normal Serum creatinine greater than 1.7 mg.dL Urine output &lt; 0.5 mL/hr/kg over the prior 24 hours Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study Cohort 2:</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>121 Days</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>rifampin</keyword>
	<keyword>infants</keyword>
</DOC>